Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Univariate analysis: Influence on OS

From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Factor Median TTP (months) 95% CI SE p =
Age > 65 years 44 vs. 43 29.77-58.23 7.26 n.s.
   37.75-48.25 2.68  
Age < 35 years 25 vs. 44 7.32-42.68 9.02 0.023
   38.5-49.5 2.81  
Stage 4 at diagnosis 43 vs. 39 37.74-48.26 2.69 n.s.
   25.96-52.04 6.66  
Grading (1,2 versus 3) 43 vs. 43 31.94-54.06 5.64 n.s.
   37.38-48.72 2.92  
Histologic type (ductal versus lobular) 43 vs. 52 38.35-47.65 2.37 n.s.
   8.41-95.6 22.24  
Positive hormone receptor status 47 vs. 39 38.4-55.61 4.39 0.075
   31.95-46.05 5.6  
Time to recurrence < 12 months 46 vs. 42 41.52-50.48 2.29 n.s.
   35.7-48.3 3.21  
Visceral metastases 40 vs. 53 33.82-46.18 3.16 n.s.
   42-62 5.1  
Number of metastatic sites (1 versus 2) NR* vs. 37 na§ na§ 0.003
   27.35-46.65 4.92  
Number of metastatic sites (2 versus > 2) 46 vs. 33 35.24-56.73 5.49 0.010
   19.56-46.44 6.86  
Trastuzumab from first-line palliative treatment 43 vs. 33 38.65-47.35 2.2 n.s.
   9.02-57.98 12.75  
Response to first-line trastuzumab-based therapy 46 vs. 42 36.33-55.67 4.94 n.s.
   34.5-49.5 3.82  
New metastatic sites at progression upon first-line trastuzumab-based therapy 44 vs. 42 26.05-61.96 9.16 n.s.
   29.69-54.31 6.38  
Development of brain metastases 33 vs. 46 32.81-43.19 2.9 0.010
   40.32-51.69 5.2  
Early development of brain metastases 19 vs. 44 9.11-28.89 2 < 0.001
   40.07-47.93 5.05  
  1. * NR: Median OS not reached
  2. § na: Not available